Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.

BMJ case reports - 19 Apr 2014

Mokrim Maha, Aftimos Philippe G, Errihani Hassan, Piccart-Gebhart Martine

Abstract excerpt

Despite many treatment advances, metastatic breast cancer remains an incurable disease and is the third leading cause of cancer-related deaths in Europe. Capecitabine has become a standard treatment option for metastatic breast cancer, as a single agent or in combination. Hand-foot syndrome and diarrhoea are the most frequently reported side effects, while capecitabine-related ileitis is very rare. Deficiency of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Capecitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Ductal

Share to Colitis

Share to Contraindications

Share to Deoxycytidine

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 24748142
DOI: 10.1136/bcr-2014-203647
PMCID: PMC3992533

Genes

DPYD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.PMID 24748142Read ↗

Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant.Semantic proximity Read ↗

Ileal metastasis of breast cancer in a patient with a BRCA2 gene mutation: report of a case.Semantic proximity Read ↗

Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) geneSemantic proximity Read ↗

Capecitabine-induced severe adverse events-therapeutic drug monitoring and DPYD-gene analysis are recommended.Semantic proximity Read ↗

Polymorphisms of MTHFR and TYMS predict capecitabine‐induced hand‐foot syndrome in patients with metastatic breast cancerSemantic proximity Read ↗

Phenotype/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case Report.Semantic proximity Read ↗

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.Semantic proximity Read ↗

Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYDSemantic proximity Read ↗

Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.Semantic proximity Read ↗

[Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].Semantic proximity Read ↗

A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.Semantic proximity Read ↗

Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.